Johnson & Johnson (NYSE:JNJ) reported a robust start to 2026 on Tuesday, posting a 9.9% increase in reported sales and raising its full-year financial guidance.
The results were bolstered by a series of high-profile regulatory approvals and strong operational growth across its Innovative Medicine and MedTech divisions.
For the first quarter of 2026, the healthcare giant reported total sales of $24.1 billion.
Operational growth stood at 6.4%, while adjusted operational growth—which accounts for the impact of acquisitions and divestitures—rose 5.3%.
The company posted earnings per share (EPS) of $2.14, with adjusted EPS reaching $2.70, reflecting the firm’s continued ability to maintain margins despite global inflationary pressures.
The quarter was defined by significant pipeline progress.
J&J highlighted the landmark approval of ICOTYDE, the industry’s first-and-only targeted oral peptide for plaque psoriasis, which management expects to be a major growth driver in the immunology sector.
Additionally, the company secured expanded labels for its oncology portfolio, specifically for TECVAYLI in combination with DARZALEX FASPRO as a second-line treatment for multiple myeloma.
In the MedTech segment, J&J made strides in Europe with the launch of VARIPULSE Pro, featuring a new pulse sequence that is five times faster than previous iterations, and the introduction of the TECNIS PureSee intraocular lens for cataract patients in the United States.
Confidence in the company’s trajectory led management to raise its full-year 2026 guidance.
J&J now estimates reported sales of $100.8 billion at the midpoint, representing 7% growth.
The outlook for adjusted EPS was increased to $11.55 at the midpoint, up 7.1% from prior projections.